Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-s

Oncolytics announced durability and survival data in anal cancer from GOBLET study, with 100% of res

Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-

SAN DIEGO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” o

Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-s

Completion of enrollment earlier this year and expected final PanCAN grant payment this quarter mark

New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in sever

New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in sever

Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-s

SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics”

Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-s

Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently

Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-s

Oncolytics announced positive preclinical results evaluating pelareorep in combination with a pan-RA

Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Oncolytics Biotech (NASDAQ:ONCY) wi

Company received written feedback from the U.S. Food and Drug Administration ("FDA") regardi

FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 0

Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-

Designation supports development in an estimated $1 billion market where there are no FDA-approved t

REO 033 builds upon the previously reported REO 022 study, which more than doubled historical standa

Half of planned clinical sites will be activated this month; more than 20 patients have been pre-ide

Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's

Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-

Intellectual property update confirms pelareorep's unique manufacturing process and scalability Prev

Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-s

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” o

Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-s

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” o

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) w

Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specif

Oncolytics Biotech, Inc. (NASDAQ:ONCY) shares are up on Monday as the company reported promising dur

2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Mo

Company to leverage strong durability and survival data in second-line and later metastatic squamous

Oncolytics is narrowing Pelareorep development toward anal cancer and metastatic colorectal cancer,

Oncolytics Biotech (NASDAQ: ONCY - Get Free Report) and Erasca (NASDAQ: ERAS - Get Free Report) are

SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics”

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earning

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report q